NextGen Homologous Recombination Deficiency Panel , Tissue
NextGen Homologous Recombinant Deficiency Panel by NGS, FFPE Tissue** Price
Brief Details
What Is a NextGen Homologous Recombination Deficiency Panel Tissue?
A NextGen Homologous Recombination Deficiency Panel Tissue is an advanced genetic test that analyses cancer tissue samples using Next-Generation Sequencing (NGS) technology. This test examines your tumour's DNA to identify specific weaknesses in how cancer cells repair damage to their genetic material.
The test helps doctors determine whether your cancer has homologous recombination deficiency, which makes certain targeted treatments more effective for your specific condition.
What Does the NextGen Homologous Recombination Deficiency Panel Tissue Measure?
This comprehensive test evaluates your cancer tissue's genetic characteristics to guide personalised treatment decisions:
- DNA repair gene mutations: Identify harmful changes in genes like BRCA1, BRCA2, and other essential DNA repair genes.
• HRD score calculation: Measures genomic instability patterns that indicate deficient homologous recombination repair mechanisms.
• Genomic scarring patterns: Detects specific damage signatures left by faulty DNA repair systems over time.
• Treatment response prediction: Determines the likelihood of responding to PARP inhibitor medications.
• Hereditary mutation detection: Identifies both inherited and acquired genetic changes affecting DNA repair.
NextGen Homologous Recombination Deficiency Panel Tissue: Who Needs It and Why It's Done
What Symptoms May Call for a NextGen Homologous Recombination Deficiency Panel Tissue?
This test doesn't diagnose symptoms directly, as HRD is a characteristic of cancer tissue rather than a condition causing specific symptoms. However, your doctor may recommend this test if you've been diagnosed with certain cancers that commonly show symptoms such as abdominal bloating, pelvic discomfort, changes in bowel habits, or feeling full quickly.
Who Should Get a NextGen Homologous Recombination Deficiency Panel Tissue?
This specialised test is recommended for specific cancer patients to guide their treatment decisions:
- Patients with advanced cancers: Those diagnosed with ovarian cancer with symptoms such as abdominal bloating, pelvic discomfort, changes in bowel habits, or feeling full quickly
• Recurrent cancer cases: Individuals whose cancer has returned after initial treatment
• Family history patients: Those with a strong family history of breast or ovarian cancer, suggesting inherited mutations.
• Treatment planning candidates: Patients being considered for targeted therapy with PARP inhibitors.
Why Is a NextGen Homologous Recombination Deficiency Panel Tissue Done?
This test is performed to enable precision medicine by identifying whether your cancer has a specific vulnerability that can be targeted with PARP inhibitor drugs. It helps your oncologist choose the most effective treatment approach based on your cancer's unique genetic characteristics.
Importance of a NextGen Homologous Recombination Deficiency Panel Tissue
The NextGen HRD Panel represents a crucial advancement in precision oncology, offering hope and clarity in your cancer care journey. By identifying specific genetic vulnerabilities in your tumour, this test helps your medical team select the most effective treatments tailored specifically for your condition.
When your cancer shows homologous recombination deficiency, it means the primary DNA repair system is compromised. PARP inhibitor medications can then block the backup repair system, causing cancer cells to die while leaving healthy cells largely unaffected. This targeted approach often results in better treatment outcomes, improved quality of life, and reduced side effects compared to traditional chemotherapy.
The test serves as a predictive biomarker, helping your medical team make informed decisions about your treatment journey with confidence and precision.
NextGen Homologous Recombination Deficiency Panel Tissue Booking & Reports – Metropolis Healthcare India
How to Book a NextGen Homologous Recombination Deficiency Panel Tissue?
- Simple Online Booking
Booking can be done through the Metropolis Healthcare App or website. Select the 'NextGen Homologous Recombination Deficiency Panel Tissue', choose a convenient time slot, and visit the nearest Metropolis Lab.
- Sample Tracking Updates
Stay informed at every step. From collection to testing, you can track your sample directly through the Metropolis Healthcare website.
- Accurate Laboratory Testing
Your sample is processed at our NABL & CAP accredited laboratories, where expert technicians ensure accurate results.
- Quick & Easy Reports
Receive your test reports promptly via email, WhatsApp, or by downloading them directly from the Metropolis Healthcare website or app.
Is Home Sample Collection for the NextGen Homologous Recombination Deficiency Panel Tissue Available Near You?
No, Metropolis Healthcare does not provide home sample collection for the NextGen Homologous Recombination Deficiency Panel Tissue test. This specialised test requires tumour tissue samples that are typically collected during medical procedures like biopsies or surgeries at healthcare facilities. Our team coordinates with your healthcare provider to ensure your tissue sample reaches our NABL & CAP accredited pathology lab safely.
How Long Does It Take to Get a NextGen Homologous Recombination Deficiency Panel Tissue Report?
Reports are usually available within 4 weeks once the sample reaches the lab.
Note: Reporting time may vary depending on your location.
Where Can I See or Get NextGen Homologous Recombination Deficiency Panel Tissue Results?
Test results from Metropolis Healthcare can be accessed through multiple convenient channels. You can log in to the Metropolis website using your credentials or use the Metropolis Healthcare App to view and download your reports. Additionally, test reports are sent via email or WhatsApp, and you also have the option to collect a physical copy directly from the lab.
Interpreting NextGen Homologous Recombination Deficiency Panel Tissue Results
What Your NextGen Homologous Recombination Deficiency Panel Tissue Results May Indicate
Your test results provide crucial information about your tumour's genetic characteristics and treatment options:
|
Parameters |
Result Interpretation |
Clinical Significance |
|
HRD Score |
≥50.0 indicates HRD-positive status. |
High scores suggest eligibility for PARP inhibitor therapy. |
|
Somatic HRR Study |
Clinically significant variants detected or not detected |
Acquired genetic changes in tumour cells, affecting treatment response |
Conditions that May Affect NextGen Homologous Recombination Deficiency Panel Tissue Accuracy
Several factors related to tissue sample quality and processing can influence your test results:
- Tissue sample quality: Poorly preserved or inadequate tissue samples may affect genetic analysis accuracy.
• Tumour content percentage: Low cancer cell content in the tissue sample may impact mutation detection.
• Sample age and storage: Older samples or those stored improperly may show DNA degradation.
• Previous treatments: Chemotherapy or radiation therapy may alter tissue DNA quality.
• Fixation methods: Improper tissue fixation during biopsy processing can affect genetic material integrity.
• Sample contamination: Normal tissue mixed with cancer tissue may dilute genetic findings.
How Is a NextGen Homologous Recombination Deficiency Panel Tissue Done?
The HRD test involves several carefully coordinated steps to ensure accurate genetic analysis:
- Tissue sample collection: Your doctor obtains tumour tissue during a biopsy or surgical procedure.
• Sample preparation: The tissue is processed and embedded in paraffin blocks for preservation.
• DNA isolation: Genetic material is carefully extracted from cancer cells within the tissue sample.
• Library preparation: DNA is prepared for sequencing using specialised protocols for Next-Generation Sequencing.
• NGS sequencing: Advanced NGS sequencing technology reads millions of DNA sequences simultaneously.
• Bioinformatics analysis: Sophisticated computer algorithms analyse sequence data to identify mutations and calculate HRD score.
• Clinical interpretation: Expert pathologists review findings and provide treatment-relevant recommendations.
How Should You Prepare for a NextGen Homologous Recombination Deficiency Panel Tissue?
Preparing for your HRD test involves coordination with your medical team:
- No dietary restrictions: Your food intake does not affect tissue-based genetic testing.
• Continue regular medications: Most medications don't interfere with the genetic analysis of tissue samples.
• Provide a complete medical history: Share details about previous treatments, family history, and current health conditions.
• Bring histopathology reports: Ensure your doctor has access to previous tissue analysis results.
• Arrange medical prescription: This specialised test requires a prescription from your oncologist.
• Discuss timing: Coordinate with your treatment schedule, as results may influence therapy decisions.
Diseases that a NextGen Homologous Recombination Deficiency Panel Tissue Can Help Detect
This advanced genetic test provides valuable information for managing ovarian cancer, helping determine eligibility for PARP inhibitor maintenance therapy in patients with platinum-sensitive disease.
NextGen Homologous Recombination Deficiency Panel Tissues/Packages that You Can Book With Metropolis Healthcare
Metropolis Healthcare offers comprehensive cancer screening packages that complement your HRD testing:
|
Test/Package Name |
Purpose/Highlights |
|
Complete ovarian cancer screening with multiple tumour markers for early detection and monitoring |
|
|
Comprehensive breast cancer assessment, including hormone receptors and HER2 status |
|
|
Complete prostate health evaluation, including PSA and related markers for cancer screening |
Frequently asked questions
Find quick answers to the most common questions about health tests, bookings, and reports.
Regular exercise, a balanced diet, avoiding smoking, maintaining a healthy weight, and managing stress all help reduce heart disease risk.
Common signs include irritability, trouble sleeping, headaches, difficulty concentrating, and muscle tension.
Ratings & Reviews
We're satisfying our customers every day since 1980.
Choose precision On time, every time!
- 98% on time collections with a 60 minutes promise
- Real-time tracking of phlebotomist arrival and report generation
- Fully digital report delivery—view from mobile or desktop instantly
- Continuous monitoring of turnaround times to ensure accuracy and speed
- Dedicated support team to resolve any delays or queries quickly
Why Metropolis Healthcare?
Metropolis has been present for over 40 years in the market.
Metropolis has a team of 200 senior pathologists and over 2000 technicians delivering diagnostic solutions in the areas of routine, semi specialty and super specialty domains like Oncology, Neurology, Gynaecology, Nephrology and many more.
0
Years of experience
170+
Advanced Labs
Trusted by
Leading Doctors & Hospitals
2,000+
Scientific Officers
Proficiency Testing
for Accurate Reports
Latest Blogs & News
Stay informed with our expert insights and updates.
About Us
Metropolis Healthcare is a leading diagnostic service provider in India. We are a team of dedicated professionals committed to ensuring you and your family receive the most accurate and timely healthcare solutions. We believe in making health care accessible, affordable and evidence-based. Our expert panel are equipped with the latest technology and manned by a certified team of over 4000+ technicians.
In diagnostic services, we have more than three decades of experience servicing diverse stakeholders health advantage packages for men, women and seniors, genetic fitness & corporation in over 650+ tests like Oncology, Neurology, Gynaecology, Haematology, and many more. Our diagnostic services are located in leading doctors and clinics and serve over 15+ cities in India.